According to the NASPGHAN clinical practice guidelines for the diagnosis and treatment of NAFLD in children (56), there are limitations with using ALT as the preferred first-line screening indicator due to its inadequate sensitivity and specificity (57, 58). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.